This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Moody's Downgrades WBA's Outlook: Should You Hold or Sell the Stock?
by Moumi Mondal
Despite Moody's latest negative rating, Walgreens' focus on operational turnaround and improving cash flows makes it a good hold.
CVS Health's Pre-Q4 Earnings: Time to Buy, Hold or Sell the Stock?
by Urmimala Biswas
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.
Should Walgreens Stock Be in Your Portfolio Before Q1 Earnings?
by Moumi Mondal
WBA's fiscal 2025 first-quarter results are expected to continue to reflect a soft U.S. Retail Pharmacy performance.
CVS Stock Trades Near 52-Week Low: Should You Buy the Dip?
by Urmimala Biswas
CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the resumption of member redeterminations.
CVS' High Utilization & MBR to Cut 2024 Profits: Is the Stock a Sell?
by Urmimala Biswas
The persistently elevated utilization of medical services is significantly putting pressure on CVS Health's Health Care Benefits segment.
Estimates for CVS Southbound After Rocky Q3: How to Play the Stock
by Urmimala Biswas
CVS Health expects the elevated levels of utilization to continue to put pressure on its 2024 performance and as a result could not provide an outlook for 2024.
Herbalife Ltd (HLF) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Herbalife Ltd (HLF) delivered earnings and revenue surprises of 200% and 0.67%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Q3 Estimates Plunge Before Earnings Release: How to Play the Stock
by Urmimala Biswas
CVS Health faces outpatient and supplemental benefits pressure within Health Care Benefits.
WBA Stock Up 16% on New Restructuring Strategy: How to Play the Stock
by Urmimala Biswas
Walgreens Boots is currently going all out to reform its pharmacy model by aggressively liquidating its unprofitable stores and businesses.
Walgreens Boots Alliance (WBA) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 8.33% and 5.07%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?
Assessing WBA Before Q4 Earnings: How Should You Play the Stock?
by Moumi Mondal
A challenging retail environment and pharmacy trends are expected to cloud Walgreens' performance in the fourth quarter of fiscal 2024.
CVS Stock Hits 50-Day SMA on Split Rumors: How Should You Play?
by Urmimala Biswas
The market speculates that following the FTC notice, several investors are pushing CVS Health to go for segment breakups.
WBA Stock Dips 5% Post Fed Rate Cut: Should You Sell Walgreens Boots?
by Urmimala Biswas
WBA is currently facing challenges within its U.S. Retail Pharmacy segment due to an unfavorable consumer environment and adverse pharmacy industry trends.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon are part of the Zacks Industry Outlook article.
3 Stocks to Avoid From The Volatile Retail Pharmacy Industry
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS, WBA and HLF are likely to be affected by reimbursement challenges that are hurting the overall health of the industry.
CVS Stock Tanks 27.5% Year to Date: Time to Buy the Dip?
by Urmimala Biswas
While CVS Health has been grappling with pharmacy reimbursement pressure, a turnaround might be in the cards, given its several strategic initiatives.
The Zacks Analyst Blog CVS Health, Walgreens and Herbalife
by Zacks Equity Research
CVS Health, Walgreens and Herbalife are included in this Analyst Blog.
What is the Right Approach for CVS Health (CVS) Post Q2 Results?
by Urmimala Biswas
The near-term challenges for CVS Health (CVS) are no doubt worrisome. Yet, the company remains focused on its strategic moves, utilizing integrated healthcare models and technological advancements.
Herbalife Ltd (HLF) Tops Q2 Earnings Estimates
by Zacks Equity Research
Herbalife Ltd (HLF) delivered earnings and revenue surprises of 25.58% and 3.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Stock Pre-Q2 Earnings: To Buy or Not to Buy?
by Urmimala Biswas
CVS Health (CVS) is grappling with a sudden increase in Medicare Advantage members' utilization trend. The Medicaid business, too, is expected to have experienced medical cost pressure in the second quarter.
CVS Health (CVS) Falls 24% in 3 Months: Should You Buy the Dip?
by Urmimala Biswas
While CVS Health (CVS) has been grappling with the pharmacy reimbursement pressure, a turnaround might be in the cards given its several strategic initiatives.
2 Stocks to Watch & One to Avoid From the Volatile Retail Pharmacy Industry
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like WBA and HLF are likely to gain despite reimbursement challenges that are hurting the overall health of the industry. CVS might struggle in the face of economic challenges.
Herbalife Ltd (HLF) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Herbalife Ltd (HLF) delivered earnings and revenue surprises of 32.43% and 0.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Ideas feature highlights: Herbalife and Boeing
by Zacks Equity Research
Herbalife and Boeing have been highlighted in this Investment Ideas article.
Navigate Bearish Markets With This Pattern
by Andrew Rocco
It's critical for investors to recognize bearish patterns to survive downtrending bearish markets. The bear flag pattern is simple and easy to identify, and is the most effective bearish technical pattern.